Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival

Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma

(2015) Sheng Han et al.   BMC CANCER

Neutrophils: important contributors to tumor progression and metastasis

(2015) Agnieszka Swierczak et al.   CANCER AND METASTASIS REVIEWS

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

(2015) Stuart A. Grossman et al.   Journal of the National Comprehensive Cancer Network

Neutrophils support lung colonization of metastasis-initiating breast cancer cells

(2015) Stefanie K. Wculek et al.   NATURE

The Emerging Role of Neutrophil to Lymphocyte Ratio in Determining Colorectal Cancer Treatment Outcomes: A Systematic Review and Meta-Analysis

(2014) George Malietzis et al.   ANNALS OF SURGICAL ONCOLOGY

Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio

(2014) Arnoud J. Templeton et al.   CANCER

Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression

(2014) Mairéad G. McNamara et al.   JOURNAL OF NEURO-ONCOLOGY

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Primary Liver Cancer: A Meta-Analysis

(2014) Tong-Chun Xue et al.   PLoS One

Neutrophils Promote the Malignant Glioma Phenotype through S100A4

(2013) J. Liang et al.   CLINICAL CANCER RESEARCH

The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme

(2013) R. M. Bambury et al.   JOURNAL OF NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

IFN-γ-Stimulated Neutrophils Suppress Lymphocyte Proliferation through Expression of PD-L1

(2013) Stan de Kleijn et al.   PLoS One

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

(2012) S. Cedrés et al.   Clinical & Translational Oncology

Elevated White Blood Cell Count at the Time of Recurrence Diagnosis Is an Indicator of Short Survival in Patients With Recurrent Cervical Cancer

(2012) Seiji Mabuchi et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer

(2012) Hiroshi Sato et al.   WORLD JOURNAL OF SURGERY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF- 

(2011) J. Lohr et al.   CLINICAL CANCER RESEARCH

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme

(2011) C. E. Fadul et al.   NEURO-ONCOLOGY

Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone

(2010) Michael P. Gustafson et al.   NEURO-ONCOLOGY

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

Peripheral Blood Neutrophils as Independent Immunologic Predictor of Response and Long-Term Survival upon Immunotherapy in Metastatic Renal-Cell Carcinoma

(2008) Jens Atzpodien et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS